Mike McAlduff - Sona Nanotech Director Founder
SNANF Stock | USD 0.19 0.00 0.00% |
Insider
Mike McAlduff is Director Founder of Sona Nanotech
Phone | 902-442-0653 |
Web | https://www.sonanano.com |
Sona Nanotech Management Efficiency
The company has return on total asset (ROA) of (2.3852) % which means that it has lost $2.3852 on every $100 spent on assets. This is way below average. Sona Nanotech's management efficiency ratios could be used to measure how well Sona Nanotech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | INSIDER Age | ||
Andrew Quong | Standard Biotools | N/A | |
Hanjoon Kim | Standard Biotools | 53 | |
David Noble | Star Equity Holdings | 52 | |
Andrew Macan | Neuronetics | 51 | |
Martin Shirley | Star Equity Holdings | 62 | |
Bobbi Coffin | Biodesix | N/A | |
Mark Hazeltine | Exagen Inc | 50 | |
Gary Pestano | Biodesix | 57 | |
MBA MBA | Sera Prognostics | 70 | |
Martin Shirley | Star Equity Holdings | 61 | |
Steven Graves | Sera Prognostics | N/A | |
Claire Sears | Neuronetics | N/A | |
Matthew Molchan | Star Equity Holdings | 56 | |
Paul Beresford | Biodesix | N/A | |
Nadia Altomare | Sera Prognostics | 53 | |
Dov Oppenheim | DarioHealth Corp | N/A | |
Matt Stauffer | Biodesix | N/A | |
Ryan Douglas | Exagen Inc | N/A | |
Shaokun Chuai | Burning Rock Biotech | 45 | |
MingChou Lee | Exagen Inc | N/A | |
Ryan Siurek | Biodesix | 52 |
Management Performance
Return On Asset | -2.39 |
Sona Nanotech Leadership Team
Elected by the shareholders, the Sona Nanotech's board of directors comprises two types of representatives: Sona Nanotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sona. The board's role is to monitor Sona Nanotech's management team and ensure that shareholders' interests are well served. Sona Nanotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sona Nanotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
David Regan, Chief Officer | ||
Darren Rowles, Pres Officer | ||
Robert Randall, CFO Sec | ||
Gerrard Marangoni, CoFounder Board | ||
Kulbir Singh, CoFounder RD | ||
Mike McAlduff, Director Founder |
Sona Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Sona Nanotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Asset | -2.39 | |||
Current Valuation | 5.72 M | |||
Shares Outstanding | 68.99 M | |||
Shares Owned By Insiders | 13.60 % | |||
Price To Book | 21.86 X | |||
EBITDA | (10.28 M) | |||
Net Income | (10.37 M) | |||
Cash And Equivalents | 402.77 K | |||
Cash Per Share | 0.01 X | |||
Total Debt | 700.76 K |
Currently Active Assets on Macroaxis
Other Information on Investing in Sona OTC Stock
Sona Nanotech financial ratios help investors to determine whether Sona OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sona with respect to the benefits of owning Sona Nanotech security.